Development of a process to manufacture PEGylated orally bioavailable insulin

Biotechnology Progress

Volumn 26, Issue 6, 2010, Pages 1695-1704

  Hazra, Partha ^a   Adhikary, Laxmi ^a   Dave, Nitesh ^a   Khedkar, Anand ^a   Manjunath, H S ^a   Anantharaman, Ramya ^a   Iyer, Harish ^a  

^a Biocon Limited   (India)

Author keywords

Conjugated insulin; Conjugation; Crystallization; IN 105; PEGylation

Indexed keywords

AMINO ACID RESIDUES; AMINO GROUP; ANALYTICAL METHOD; CHEMICAL STRUCTURE; CONJUGATED INSULIN; CONJUGATED MOLECULES; CONJUGATION; CONJUGATION PROCESS; COVALENT ATTACHMENT; DOSE-DEPENDENT; FREE AMINO GROUPS; HETEROGENEOUS MIXTURES; IN-105; INSULIN MOLECULES; METHOXY; METHOXYPOLYETHYLENE GLYCOL; N-TERMINALS; PEGYLATION; PEPTIDE MAPPING; PROCESS DEVELOPMENT; REACTION CONDITIONS; RP-HPLC; SOLVENT CONCENTRATION; TYPE-2 DIABETES;

AMINO ACIDS; CHEMICAL ANALYSIS; CRYSTALLIZATION; GLUCOSE; GROUP TECHNOLOGY; MOLECULES; MOTION PICTURE EXPERTS GROUP STANDARDS; ORGANIC POLYMERS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; PURIFICATION;

INSULIN;

INSULIN; MACROGOL DERIVATIVE;

ARTICLE; CHEMISTRY; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION AND PURIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; TABLET;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INSULIN; POLYETHYLENE GLYCOLS; TABLETS;

EID: 78650186402     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.487     Document Type: Article

References (30)

1. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev. 1995; 16: 157-182.
2. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1997; 252: 3578-3581.
3. Veronese FM, Harris JM. Peptide and protein PEGylation. III. Advances in chemistry and clinical application. Adv Drug Deliv Rev. 2008; 60: 1-2.
4. Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel. 2008; 11: 242-250.
5. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005; 21: 1451-1458.
6. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001; 22: 405-417.
7. Robert MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002; 54: 459-476.
8. Tom I, Lee V, Dumas M, Madanat M, Ouyang J, Severs J, Andersen J, Buxton JM, Whelan JP, Pan CQ. Reproducible production of a PEGylated dual-acting peptide for diabetes. AAPS J. 2007; 9: 227-234.
9. Tsubery H, Mirronchik M, Fridkin M, Shechter Y. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem. 2004; 279: 38118-38124.
10. Fuerteges F, Abuchowski A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J Controlled Release. 1990; 11: 139-148.
11. Uchio T, Baudys M, Liu F, Song SC, Kim SW. Site-specific insulin conjugation with enhanced stability and extended action profile. Adv Drug Deliv Rev. 1999; 35: 289-306.
12. Miller MA, Malkar NB, Severynse-Steven D, Yarbrough KG, Mark JB, Dugdell RE, Puskas ME, Krishnan R, Kenneth DJ. Ampiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjug Chem. 2006; 17: 267-274.
13. Chae SY, Jin C-H, Shin HJ, Youn YS, Lee S. Preparation, characterization, and application of biotinylation and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem. 2008; 19: 334-341.
14. Iyer H, Khedkar K, Verma M. Oral insulin-a review of current status. Diabetes Obes Metab. 2010; 12: 179-185.
15. Hinds K, Koh JJ, Joss L, Liu F, Baudyš M, Kim SW. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjug Chem. 2000; 11: 195-201.
16. Conan JF. Size exclusion reaction chromatography (SERC): a new technique for protein PEGylation. Biotechnol Bioeng. 2003; 82: 200-206.
17. Stainer DF. Cocrystallization of proinsulin and insulin. Nature. 1973; 243: 528-530.
18. Dave N, Hazra P, Khedkar K, Manjunath HS, Iyer H, Suryanarayan S. Process and purification for manufacture of a modified insulin intended for oral delivery. J Chromatogr. 2008; 1177: 282-286.
19. Bromberg L, Julia R-S, Scott T. Insulin particle formation in supersaturated aqueous solutions of poly(ethylene glycol). Biophys J. 2005; 89: 3424-3433.
20. Welinder BS, Sørensen HH, Bruno H. Reversed-phase high-performance liquid chromatography of insulin. Resolution and recovery in relation to column geometry and buffer composition. J Chromatogr. 1986; 361: 357-367.
21. Welinder BS, Linde S. InCRC Handbook of HPLC for the Separation of Amino Acids, Peptides and Proteins, II Hancock WS Ed, Boca Raton, FL: CRC Press, 1984; 357-362.
22. Mandrup G. In-process control of insulin production by high-performance liquid chromatography. Trends Anal Chem. 1992; 11: 389-395.
23. Lee H, Park TG. A novel method for identifying PEGylation sites of protein using biotinylated PEG derivatives. J Pharm Sci. 2003; 92: 97-103.
24. Michael JR, Milton JH. Attachment of degradable poly(ethylene glycol) to protein has the potential to increase therapeutic efficacy. J Pharm Sci. 1998; 87: 1440-1445.
25. Gordon SJ. Development of oral insulin: progress and current status. Diabetes Metab Res Rev. 2002; 18: 29-37.
26. Khedkar A, Iyer H, Anand A, Verma1 M, Krishnamurthy S, Savale S, Atignal A. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab. 2010; 12: 659-664.
27. Hooftman G, Herman S, Schacht S. Polyethylene glycols with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polym. 1996; 11: 135-159.
28. David CW, Voloch M, Lee S, Liu Y-H, Susan C-C, Collette C, Pramanik B. Carboxyalkylated histidine is a pH dependent product of PEGylation with SC-PEG. Pharm Res. 2001; 18: 354-1360.
29. Lee S-H, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem. 2005; 16: 377-382.
30. Katre NV, Knauf MJ, Lorivol WJ. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv Drug Deliv Rev. 1993; 10: 91-114.